Borderline Resectable Pancreatic Cancer: Definitions and the Importance of Multimodality Therapy

@article{Evans2010BorderlineRP,
  title={Borderline Resectable Pancreatic Cancer: Definitions and the Importance of Multimodality Therapy},
  author={Douglas B. Evans and Beth A. Erickson and Paul S. Ritch},
  journal={Annals of Surgical Oncology},
  year={2010},
  volume={17},
  pages={2803-2805}
}
The exceedingly high rates of distant metastatic recurrence following successful surgical resection of early-stage tumors would suggest that pancreatic adenocarcinoma is a systemic disease at the time of diagnosis in the vast majority of patients, and therefore a compelling case can be made for a neoadjuvant treatment approach in almost all patients. Although the first national trial of neoadjuvant therapy for resectable pancreatic cancer (ACOSOG Z5041) only recently opened, single-institution… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Similar Papers

Loading similar papers…